AstraZeneca is to receive up to $400 million from Takeda after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson’s disease.
AstraZeneca forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting.
CSL Ltd. bought Tucson, Ariz.-based Calimmune for $91 million upfront and up to $325 million in performance-based milestones.
Takeda and BioSurfaces announced a deal to initiate a research program designed to develop innovative medical devices to treat patients with GI diseases.
French drugmaker Sanofi boosted its early-stage pipeline in immunology by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).
Novartis CEO Joe Jiminez spoke with investors and analysts regarding the company’s half-year financials.
OncoMed announced GlaxoSmithKline was terminating its nearly 10-year-old R&D agreement. OncoMed’s shares fell about 2 percent on the news.
Tokyo-based Daiichi Sankyo Company announced that it was ending its development deal of CHS-0214 with Coherus Biosciences.
The world’s leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines.